Top Markets
#1 Akedo Akedo +111.38%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +48.38%
#4 Black Phoenix Black Phoenix +34.09%
#5 Velvet Velvet +33.20%
#6 Cross Cross +32.71%
#7 OVERTAKE OVERTAKE +17.22%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +15.83%
#9 Bitway Bitway +14.87%
#10 QANplatform QANplatform +14.54%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
AIM ImmunoTech Inc. AIM ImmunoTech Inc.

AIM ImmunoTech Inc.

AIM
Rank in Stocks #38741
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida,... AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
Share Price
$0.2442
Market Cap
$831.14K
Change (1 day)
-5.46%
Change (1 year)
-89.91%
Country
US
Trade AIM ImmunoTech Inc. (AIM)

Category

Healthcare
Revenue for AIM ImmunoTech Inc. (AIM)
Revenue in Aug 2026 TTM: 0
According to AIM ImmunoTech Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for AIM ImmunoTech Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE